Risk factors for recurrence of esophageal squamous cell carcinoma after pathological complete response to neoadjuvant therapy followed by esophagectomy
World Journal of Surgery · 2024-07 · 48 (7) · 1700-1709
DOI: 10.1002/wjs.12212 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Surgery, online erschienen am 17.05.2024. Verfasst von Ryosuke Hirohata und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan. Hauptthemen laut MEDLINE: Esophagectomy, Neoadjuvant Therapy, Neoplasm Recurrence, Local, Esophageal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Prognosis of patients who achieve pathological complete response (pCR) with neoadjuvant therapy (NAT) is better than that of non‐pCR patients. Currently, there is no indication for adjuvant immune checkpoint inhibitor therapy after achieving pCR. However, recurrence risk after pCR is reportedly 10%–20% with a poor prognosis. Therefore, we investigated the preoperative risk factors for recurrence in patients with pCR.
Methods
We analyzed 56 patients with esophageal squamous cell carcinoma who underwent esophagectomy after neoadjuvant chemoradiotherapy (NACRT) or neoadjuvant chemotherapy (NAC) and were histologically diagnosed with pCR. Preoperative factors were compared between patients with and without recurrence to identify the risk factors.
Results
Forty‐eight patients who achieved pCR received NACRT and 8 received NAC. Ten patients who experienced recurrence (17.9%) had undergone NACRT. The cN2 lesions were more frequent, and pre‐NAT blood hemoglobin (Hb) was lower in the recurrence group. In addition, the pre‐NAT cross‐sectional area (CSA) product of the major and minor diameters of the primary tumor before NAT was significantly higher in recurrent cases ( p = 0.041). Multivariate analysis, including the cTNM stage, pre‐NAT Hb, and pre‐NAT CSA, identified high pre‐NAT CSA as the only risk factor for recurrence (odds ratio 11.6, 95% confidence interval 1.3–104.1, and p = 0.028). Cox regression analysis of recurrence‐free and overall survival identified only high pre‐NAT CSA as a prognostic factor.
Conclusions
The recurrence risk is relatively high even in patients who achieve pCR after NAT. High pre‐NAT CSA of the primary tumor is a risk factor for recurrence necessitating close surveillance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
ORCID-Profile: Yoichi Hamai
Zitieren
APA
Hirohata, R., Hamai, Y., Emi, M., Ibuki, Y., Kurokawa, T., Ohsawa, M., Kitasaki, N., & Okada, M. (2024). Risk factors for recurrence of esophageal squamous cell carcinoma after pathological complete response to neoadjuvant therapy followed by esophagectomy. World Journal of Surgery, 48(7), 1700-1709. https://doi.org/10.1002/wjs.12212
Vancouver
Hirohata R, Hamai Y, Emi M, Ibuki Y, Kurokawa T, Ohsawa M, et al. Risk factors for recurrence of esophageal squamous cell carcinoma after pathological complete response to neoadjuvant therapy followed by esophagectomy. World Journal of Surgery. 2024;48(7):1700-1709. doi:10.1002/wjs.12212
BibTeX
@article{Hirohata2024,
author = {Hirohata, Ryosuke and Hamai, Yoichi and Emi, Manabu and Ibuki, Yuta and Kurokawa, Tomoaki and Ohsawa, Manato and Kitasaki, Nao and Okada, Morihito},
title = {Risk factors for recurrence of esophageal squamous cell carcinoma after pathological complete response to neoadjuvant therapy followed by esophagectomy},
journal = {World Journal of Surgery},
year = {2024},
volume = {48},
number = {7},
pages = {1700--1709},
doi = {10.1002/wjs.12212}
}
EUVIMED